NOG-hIL-6 Tg (NOG-IL6)	NOG-hIL-6 Tg

• You will be required to sign a consent form upon purchase.
• The use of this mouse strain corresponds to the use of Living Modified Organism (Cartagene Protocol, domestic law). We will send you an information provision form in advance, so please check it and use it according to the rules of each institution.

Development

CA vector containing the human IL-6 gene downstream of the CMV promoter was microinjected into (NOD♀ x NOG♂) F1 pronuclear stage embryos, and crossed with NOG mouse to establish them.

Product features of NOG-IL6 mouse

• This is a severely immunodeficient NOG mouse that expresses the human cytokine hIL-6.
• Differentiation of engrafted hematopoietic stem cells into monocytes is promoted.

Research Applications

• Study of tumor-infiltrating macrophages (TAM)
• IL-6 dependent acute myeloid leukemia cell transplantation host

Background data

• NOG-IL6 Body weight change
• NOG-IL6 Hematology data
• NOG-IL6 Organ weight data

• Human hematopoietic stem cells (HSCs) engrafted model is commonly used.
• We produce HSC engrafted humanized NOG-IL6 mouse in Japan and deliver them to customers.
• Production will start after receiving your firm order.
• For research targeting monocytes and macrophages, we recommend early delivery after HSC engraftment.

Product features of Humanized NOG-IL6 mouse

• HSC engrafted NOG-IL6 (hereafter: huNOG-IL6) mouse exhibited enhanced human monocyte/macrophage differentiation.
• Tumor-infiltrating macrophages of huNOG-IL6 mouse expressed high levels of CD163, a marker of immunoregulatory myeloid cells, and produced immunosuppressive molecules such as arginase-1 (Arg-1), IL-10, and VEGF.
• Such cells from huNOG-IL6 mouse, but not those from conventional huNOG mouse, suppressed the proliferation of human T cells in response to antigenic stimulation in in vitro culture.
• These results suggest that functional human TAMs can be developed in NOG-IL6 mouse and are expected to contribute to the development of new cancer immunotherapies targeting immunomodulatory/immunosuppressive myeloid cells.
  （Modified the abstract of the reference. Hanazawa et al. Front Immunol. 2018）
• We are providing detailed briefings by online regarding the characteristics of humanized NOG-IL6 mouse, the production of humanized NOG-IL6 mouse, and experimental protocols for their use. Please feel free to contact us at sales@invivoscience.com.

Back ground data

• NOG-IL6:Each cell ratio after Human HSC engraftment